ArticleScientific reports2025
Immature platelet fraction and bone marrow findings in hematology.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Artificial intelligence prediction of therapy response in newly diagnosed adult severe primary immune thrombocytopenia.Research and practice in thrombosis and haemostasis · 2026Article
- Establishment and evaluation of hematological and serum biochemical reference intervals in Chinese local donkey populations.BMC veterinary research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bone marrow examination (BME) and the assessment of the immature platelet fraction (IPF) are crucial diagnostic tools in hematology. The IPF is the proportion of young, newly released platelets of the total number in the peripheral circulation. We conducted a retrospective study of 1,552 patients with various hematologic disorders, evaluating the relationship between BME findings and IPF. Bone marrow aspirates and biopsies were assessed for their cellularity, the characteristics of the megakaryocytes, and the presence of dysplasia or malignant cells. The IPF was associated with BME findings and the final diagnoses made, and significantly correlated with the megakaryocyte count in patients with myelodysplastic syndrome (MDS), albeit weakly (R²=0.251, p < 0.001). Patients with immune thrombocytopenia exhibited much higher median IPFs (14.8% vs. 3.0%, respectively; p < 0.001) than those of other patients. Patients with MDS displayed wide variability in IPF (median: 6.8%, range: 0.40%-43.5%), and IPF demonstrated a high level of specificity for megakaryocyte abnormalities (p < 0.001). The study highlights the diagnostic utility of IPF in combination with BME, particularly for the differentiation of immune thrombocytopenia and the identification of megakaryocyte-related pathologies in MDS. Thus, the combined use of these two parameters could enhance diagnostic accuracy and inform treatment strategies for hematologic disorders.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.